25k is a token gesture does not show conviction. And Roche just wasted a whole year, after early approval and may be a record breaking launch, now they tell us they don't even know where the patients are. The numbers so far tell us they are not even hitting the Gorlin patients hard.
All I know is that this thing is looking at 3 potentially major catalysts in the near future, the least of which is the earnings report and the corresponding sales growth to be reported from it. Both Europe and the phase II operable BCC results (which as far as I know are still expected early in 2013) are potential game changers.